脐带血移植与来自部分 HLA 匹配的成年供体的祖细胞的组合（单倍体脐带移植）已在过去二十年中得到应用。在欧洲和美国，成人供体移植物是 CD34 选择的并提供早期造血，但持久的移植来自脐带血移植物（CD34 选择的单倍体脐带）。中性粒细胞恢复迅速，急性和慢性 GVHD 发生率较低。中国最近的研究将脐带血移植物与 T 充足的单倍体移植物（未修饰的单倍体脐带）结合起来。单倍体移植物通常会建立优势，而 UCB 嵌合现象很少被检测到。比较研究表明，与单倍体移植或 CBU 移植相比，复发率显着降低，预后得到改善，特别是对于晚期白血病患者。最近的一项前瞻性随机研究证实了这一点。 Haplo-cord 可减轻 UCB 移植的植入延迟。 UCB 移植物的独特生物学特性可降低 GVHD 并改善 GVL，尤其有益于高危疾病。

The combination of cord blood transplant with progenitor cells from partially HLA-matched adult donors (haplo-cord transplant) has been used over the past two decades. In Europe and the US the adult donor graft is CD34 selected and provides early hematopoiesis, but durable engraftment derives from the cord blood graft (CD34 selected haplo-cord). Neutrophil recovery is prompt and rates of acute and chronic GVHD are low. Recent Chinese studies combine cord blood grafts with T-replete haplo-identical grafts (unmodified haplo-cord). The haplo graft usually establishes dominance and UCB chimerism is rarely detected. Comparison studies suggest considerably decreased rates of relapse and improved outcomes, compared with either haplo-identical transplant or CBU transplant, particularly in patients with advanced leukemia. A recent prospective randomized study confirms this. Haplo-cord mitigates the engraftment delay of UCB transplant. The unique biology of UCB grafts results in low GVHD and improved GVL especially beneficial in high-risk disease.